{"preliminary_commentary":{"by_channel":{"youtube":59,"podcast":25,"x_thread":17,"x_video":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04915508\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"EXCALIBUR","nct_id":"NCT04915508","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=excalibur-nct04915508. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EXCALIBUR","arms":[{"description":"Patients undergo SBRT every other day or on consecutive days for up to 14 days. Patients may receive hormonal therapy at the discretion of the treating physician.","label":"Treatment (SBRT, hormone therapy)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Prostate Adenocarcinoma","Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8","Stage IIIC Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8"],"enrollment":{"count":165,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Hormone Therapy","otherNames":["Chemotherapy-Hormones/Steroids","Endocrine Therapy","Hormonal Therapy","hormone treatment"],"type":"DRUG"},{"name":"Stereotactic Body Radiation Therapy","otherNames":["SABR","SBRT","Stereotactic Ablative Body Radiation Therapy"],"type":"RADIATION"}],"last_update":"2026-07-17","lead_sponsor":"Jonsson Comprehensive Cancer Center","official_title":"Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for Adjuvant or Salvage Treatment for Rising PSA After Radical Prostatectomy (EXCALIBUR)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Change of Expanded Prostate Cancer Index (EPIC) score for the gastrointestinal domain","timeFrame":"Baseline up to 2 years"},{"measure":"Change of Expanded Prostate Cancer Index (EPIC) score for the genitourinary domain","timeFrame":"Baseline up to 2 years"}],"references":[],"start_date":{"date":"2021-06-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy","url":"https://clinicaltrials.gov/study/NCT04915508"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/excalibur-nct04915508"}